Stalfort John A Iii - Net Worth and Insider Trading

Stalfort John A Iii Net Worth

The estimated net worth of Stalfort John A Iii is at least $22 Million dollars as of 2024-12-27. Stalfort John A Iii is the Director of Dova Pharmaceuticals Inc and owns about 635,665 shares of Dova Pharmaceuticals Inc (DOVA) stock worth over $18 Million. Stalfort John A Iii is the Director of Taysha Gene Therapies Inc and owns about 1,933,671 shares of Taysha Gene Therapies Inc (TSHA) stock worth over $4 Million. Stalfort John A Iii is also the Director of Acumen Pharmaceuticals Inc and owns about 303,919 shares of Acumen Pharmaceuticals Inc (ABOS) stock worth over $574,407. Besides these, Stalfort John A Iii also holds Verrica Pharmaceuticals Inc (VRCA) . Details can be seen in Stalfort John A Iii's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Stalfort John A Iii has not made any transactions after 2023-08-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Stalfort John A Iii

To

Stalfort John A Iii Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Stalfort John A Iii owns 4 companies in total, including Verrica Pharmaceuticals Inc (VRCA) , Dova Pharmaceuticals Inc (DOVA) , and Acumen Pharmaceuticals Inc (ABOS) among others .

Click here to see the complete history of Stalfort John A Iii’s form 4 insider trades.

Insider Ownership Summary of Stalfort John A Iii

Ticker Comapny Transaction Date Type of Owner
VRCA Verrica Pharmaceuticals Inc 2020-08-14 director
DOVA Dova Pharmaceuticals Inc 2019-11-12 director
ABOS Acumen Pharmaceuticals Inc 2021-07-06 director
LIMIT LIMIT 2023-08-16 director

Stalfort John A Iii Latest Holdings Summary

Stalfort John A Iii currently owns a total of 4 stocks. Among these stocks, Stalfort John A Iii owns 635,665 shares of Dova Pharmaceuticals Inc (DOVA) as of December 20, 2018, with a value of $18 Million and a weighting of 79.95%. Stalfort John A Iii owns 1,933,671 shares of Taysha Gene Therapies Inc (TSHA) as of August 16, 2023, with a value of $4 Million and a weighting of 16.13%. Stalfort John A Iii also owns 303,919 shares of Acumen Pharmaceuticals Inc (ABOS) as of July 6, 2021, with a value of $574,407 and a weighting of 2.58%. The other 1 stocks Verrica Pharmaceuticals Inc (VRCA) have a combined weighting of 1.34% among all his current holdings.

Latest Holdings of Stalfort John A Iii

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
DOVA Dova Pharmaceuticals Inc 2018-12-20 635,665 28.04 17,824,047
TSHA Taysha Gene Therapies Inc 2023-08-16 1,933,671 1.86 3,596,628
ABOS Acumen Pharmaceuticals Inc 2021-07-06 303,919 1.89 574,407
VRCA Verrica Pharmaceuticals Inc 2020-08-14 462,110 0.65 299,771

Holding Weightings of Stalfort John A Iii


Stalfort John A Iii Form 4 Trading Tracker

According to the SEC Form 4 filings, Stalfort John A Iii has made a total of 0 transactions in Dova Pharmaceuticals Inc (DOVA) over the past 5 years. The most-recent trade in Dova Pharmaceuticals Inc is the acquisition of 31,000 shares on December 20, 2018, which cost Stalfort John A Iii around $194,060.

According to the SEC Form 4 filings, Stalfort John A Iii has made a total of 1 transactions in Taysha Gene Therapies Inc (TSHA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Taysha Gene Therapies Inc is the acquisition of 777,778 shares on August 16, 2023, which cost Stalfort John A Iii around $700,000.

According to the SEC Form 4 filings, Stalfort John A Iii has made a total of 1 transactions in Acumen Pharmaceuticals Inc (ABOS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Acumen Pharmaceuticals Inc is the acquisition of 35,000 shares on July 6, 2021, which cost Stalfort John A Iii around $560,000.

More details on Stalfort John A Iii's insider transactions can be found in the Insider Trading History of Stalfort John A Iii table.

Insider Trading History of Stalfort John A Iii

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Stalfort John A Iii Trading Performance

GuruFocus tracks the stock performance after each of Stalfort John A Iii's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Stalfort John A Iii is 8.88%. GuruFocus also compares Stalfort John A Iii's trading performance to market benchmark return within the same time period. The performance of stocks bought by Stalfort John A Iii within 3 months outperforms 2 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Stalfort John A Iii's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Stalfort John A Iii

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
3 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 28.06 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 24.48 LIMIT LIMIT LIMIT LIMIT LIMIT

Stalfort John A Iii Ownership Network

Ownership Network List of Stalfort John A Iii

No Data

Ownership Network Relation of Stalfort John A Iii

Insider Network Chart

Stalfort John A Iii Owned Company Details

What does Verrica Pharmaceuticals Inc do?

Who are the key executives at Verrica Pharmaceuticals Inc?

Stalfort John A Iii is the director of Verrica Pharmaceuticals Inc. Other key executives at Verrica Pharmaceuticals Inc include director & President and CEO Ted White , Chief Commercial Officer Joe Bonaccorso , and General Counsel Christopher G. Hayes .

Verrica Pharmaceuticals Inc (VRCA) Insider Trades Summary

Over the past 18 months, Stalfort John A Iii made no insider transaction in Verrica Pharmaceuticals Inc (VRCA). Other recent insider transactions involving Verrica Pharmaceuticals Inc (VRCA) include a net sale of 150,999 shares made by Ted White , a net sale of 130,386 shares made by Joe Bonaccorso , and a net sale of 124,941 shares made by Christopher G. Hayes .

In summary, during the past 3 months, insiders sold 0 shares of Verrica Pharmaceuticals Inc (VRCA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 533,677 shares of Verrica Pharmaceuticals Inc (VRCA) were sold and 2,260,199 shares were bought by its insiders, resulting in a net purchase of 1,726,522 shares.

Verrica Pharmaceuticals Inc (VRCA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Verrica Pharmaceuticals Inc Insider Transactions

No Available Data

Stalfort John A Iii Mailing Address

Above is the net worth, insider trading, and ownership report for Stalfort John A Iii. You might contact Stalfort John A Iii via mailing address: C/o Acumen Pharmaceuticals, Inc., 427 Park Street, Charlottesville Va 22902.

Discussions on Stalfort John A Iii

No discussions yet.